市场调查报告书

青蒿素联合治疗(ACT)- 全球市场预测(2017年~2026年)

Artemisinin Combination - Global Market Outlook (2017-2026)

出版商 Stratistics Market Research Consulting 商品编码 755121
出版日期 内容资讯 英文 175 Pages
商品交期: 2-3个工作天内
价格
Back to Top
青蒿素联合治疗(ACT)- 全球市场预测(2017年~2026年) Artemisinin Combination - Global Market Outlook (2017-2026)
出版日期: 2018年11月01日内容资讯: 英文 175 Pages
简介

全球青蒿素联合治疗(ACT)市场在2017年估算为3,388亿美元,预测从2017年到2026年将以10.5%的年复合成长率发展,到2026年市场规模将成长到8,309亿8,000万美元。新的抗疟疾药的登场,及青蒿素联合治疗(ACT)的需求增加,政府的举措等成为这个市场主要成长要素。

本报告提供全球青蒿素联合治疗(ACT)市场调查,市场概要,各类型、各地区的市场规模的变化与预测,市场趋势,市场成长要素及阻碍因素分析,市场机会,竞争情形,主要企业的简介等全面性资讯。

目录

第1章 摘要整理

第2章 简介

第3章 市场趋势分析

  • 简介
  • 成长要素
  • 阻碍因素
  • 市场机会
  • 威胁
  • 新兴市场
  • 今后的市场情况

第4章 波特的五力分析

  • 买方议价能力
  • 供给企业谈判力
  • 新加入业者的威胁
  • 替代品的威胁
  • 竞争企业间的敌对关系

第5章 全球青蒿素联合治疗(ACT)市场:各类型

  • 简介
  • Artesunate-Sulfadoxine-Pyrimethamine
  • Artesunate-Mefloquine
  • Artesunate-Pyronaridine
  • Artemether-Lumefantrine
  • Artesunate-Amodiaquine
  • Dihydroartemisinin-Piperaquine

第6章 全球青蒿素联合治疗(ACT)市场:各地区

  • 简介
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他
  • 南美
    • 阿根廷
    • 巴西
    • 智利
    • 其他
  • 中东、非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 卡达
    • 南非
    • 其他

第7章 市场主要趋势

  • 协定,伙伴关系,合作,合资企业
  • 收购与合并
  • 新产品的销售
  • 扩张
  • 其他主要策略

第8章 企业简介

  • KPC Pharmaceuticals, Inc.
  • Shanghai Fosun Pharmaceutical Industrial Development Company Limited
  • Sanofi
  • Desano Holdings Ltd.
  • Calyx Chemicals and Pharmaceuticals Limited
  • Mylan N.V.
  • Novartis AG
  • Denk Pharma GmbH & Co. KG
  • Hovid Berhad
  • Ipca Laboratories Limited
  • Cipla Limited
  • Aspen Pharmacare Holdings Limited
目录

According to Stratistics MRC, the Global Artemisinin Combination Therapy (ACT) market is accounted for $338.80 billion in 2017 and is expected to reach $830.98 billion by 2026 growing at a CAGR of 10.5% during the forecast period. Rising pipeline for new anti-malarial drugs, growing demand for artemisinin combination therapy (ACT) and increasing government initiatives are few factors propelling for the growth of the market. However, limited number of manufacturers globally acts as a hindrance for the market growth.

Based on type, Artesunate-Mefloquine is a lucrative market for Artemisinin Combination Therapy (ACT) due to its quick spread of resistance, mediated mainly by a raise in copy number and expression of the P. falciparum multi-drug resistance (MDR) gene. This improves bioavailability and reduces vomiting. There is no formulation of mefloquine for children. Regardless of earlier restrictions there is no cause to withhold mefloquine for young children. Limited information recommends that mefloquine is perhaps secure in pregnancy.

By geography, Middle East and Africa held the largest market share in the artemisinin combination therapy owing to have large number of production base of artemisinin herbs and growing demand in malaria endemic countries which are contributing to the expansion of the market in MEA. Though African countries, where the occurrence of malaria is high, so they have amplified malaria control strategies, efficient treatment and control, but it still presents a huge logistical difficulty. As numerous at-risk people survive in extreme poverty in isolated areas, WHO and other organizations are working on completely eradicating it in Africa and thus, over the coming years, the adoption rate of ACT is further expected to boost.

Some of the key players profiled in the Artemisinin Combination Therapy (ACT) market include KPC Pharmaceuticals, Inc., Shanghai Fosun Pharmaceutical Industrial Development Company Limited, Sanofi, Desano Holdings Ltd., Calyx Chemicals and Pharmaceuticals Limited, Mylan N.V., Novartis AG, Denk Pharma GmbH & Co. KG, Hovid Berhad, Ipca Laboratories Limited, Cipla Limited and Aspen Pharmacare Holdings Limited.

Types Covered:

  • Artesunate-Sulfadoxine-Pyrimethamine
  • Artesunate-Mefloquine
  • Artesunate-Pyronaridine
  • Artemether-Lumefantrine
  • Artesunate-Amodiaquine
  • Dihydroartemisinin-Piperaquine

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country level segments
  • Market share analysis of the top industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Futuristic Market Scenario

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Artemisinin Combination Therapy (ACT) Market, By Type

  • 5.1 Introduction
  • 5.2 Artesunate-Sulfadoxine-Pyrimethamine
  • 5.3 Artesunate-Mefloquine
  • 5.4 Artesunate-Pyronaridine
  • 5.5 Artemether-Lumefantrine
  • 5.6 Artesunate-Amodiaquine
  • 5.7 Dihydroartemisinin-Piperaquine

6 Global Artemisinin Combination Therapy (ACT) Market, By Geography

  • 6.1 Introduction
  • 6.2 North America
    • 6.2.1 US
    • 6.2.2 Canada
    • 6.2.3 Mexico
  • 6.3 Europe
    • 6.3.1 Germany
    • 6.3.2 UK
    • 6.3.3 Italy
    • 6.3.4 France
    • 6.3.5 Spain
    • 6.3.6 Rest of Europe
  • 6.4 Asia Pacific
    • 6.4.1 Japan
    • 6.4.2 China
    • 6.4.3 India
    • 6.4.4 Australia
    • 6.4.5 New Zealand
    • 6.4.6 South Korea
    • 6.4.7 Rest of Asia Pacific
  • 6.5 South America
    • 6.5.1 Argentina
    • 6.5.2 Brazil
    • 6.5.3 Chile
    • 6.5.4 Rest of South America
  • 6.6 Middle East & Africa
    • 6.6.1 Saudi Arabia
    • 6.6.2 UAE
    • 6.6.3 Qatar
    • 6.6.4 South Africa
    • 6.6.5 Rest of Middle East & Africa

7 Key Developments

  • 7.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 7.2 Acquisitions & Mergers
  • 7.3 New Product Launch
  • 7.4 Expansions
  • 7.5 Other Key Strategies

8 Company Profiling

  • 8.1 KPC Pharmaceuticals, Inc.
  • 8.2 Shanghai Fosun Pharmaceutical Industrial Development Company Limited
  • 8.3 Sanofi
  • 8.4 Desano Holdings Ltd.
  • 8.5 Calyx Chemicals and Pharmaceuticals Limited
  • 8.6 Mylan N.V.
  • 8.7 Novartis AG
  • 8.8 Denk Pharma GmbH & Co. KG
  • 8.9 Hovid Berhad
  • 8.10 Ipca Laboratories Limited
  • 8.11 Cipla Limited
  • 8.12 Aspen Pharmacare Holdings Limited

List of Tables

  • Table 1 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Region (2016-2026) (US $MN)
  • Table 2 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
  • Table 3 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Sulfadoxine-Pyrimethamine (2016-2026) (US $MN)
  • Table 4 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Mefloquine (2016-2026) (US $MN)
  • Table 5 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Pyronaridine (2016-2026) (US $MN)
  • Table 6 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether-Lumefantrine (2016-2026) (US $MN)
  • Table 7 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Amodiaquine (2016-2026) (US $MN)
  • Table 8 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin-Piperaquine (2016-2026) (US $MN)
  • Table 9 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
  • Table 10 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
  • Table 11 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Sulfadoxine-Pyrimethamine (2016-2026) (US $MN)
  • Table 12 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Mefloquine (2016-2026) (US $MN)
  • Table 13 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Pyronaridine (2016-2026) (US $MN)
  • Table 14 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether-Lumefantrine (2016-2026) (US $MN)
  • Table 15 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Amodiaquine (2016-2026) (US $MN)
  • Table 16 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin-Piperaquine (2016-2026) (US $MN)
  • Table 17 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
  • Table 18 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
  • Table 19 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Sulfadoxine-Pyrimethamine (2016-2026) (US $MN)
  • Table 20 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Mefloquine (2016-2026) (US $MN)
  • Table 21 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Pyronaridine (2016-2026) (US $MN)
  • Table 22 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether-Lumefantrine (2016-2026) (US $MN)
  • Table 23 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Amodiaquine (2016-2026) (US $MN)
  • Table 24 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin-Piperaquine (2016-2026) (US $MN)
  • Table 25 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
  • Table 26 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
  • Table 27 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Sulfadoxine-Pyrimethamine (2016-2026) (US $MN)
  • Table 28 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Mefloquine (2016-2026) (US $MN)
  • Table 29 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Pyronaridine (2016-2026) (US $MN)
  • Table 30 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether-Lumefantrine (2016-2026) (US $MN)
  • Table 31 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Amodiaquine (2016-2026) (US $MN)
  • Table 32 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin-Piperaquine (2016-2026) (US $MN)
  • Table 33 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
  • Table 34 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
  • Table 35 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Sulfadoxine-Pyrimethamine (2016-2026) (US $MN)
  • Table 36 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Mefloquine (2016-2026) (US $MN)
  • Table 37 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Pyronaridine (2016-2026) (US $MN)
  • Table 38 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether-Lumefantrine (2016-2026) (US $MN)
  • Table 39 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Amodiaquine (2016-2026) (US $MN)
  • Table 40 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin-Piperaquine (2016-2026) (US $MN)
  • Table 41 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)
  • Table 42 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)
  • Table 43 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Sulfadoxine-Pyrimethamine (2016-2026) (US $MN)
  • Table 44 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Mefloquine (2016-2026) (US $MN)
  • Table 45 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Pyronaridine (2016-2026) (US $MN)
  • Table 46 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether-Lumefantrine (2016-2026) (US $MN)
  • Table 47 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate-Amodiaquine (2016-2026) (US $MN)
  • Table 48 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin-Piperaquine (2016-2026) (US $MN)
Back to Top